GlaxoSmithKline Plc (GSK,GSK.L) said it has extended its tender offer to buy all of the outstanding shares of Human Genome Sciences (HGSI) for $13.00 per share in cash to 5:00 p.m. New York City time on June 29, 2012.
The tender offer was earlier scheduled to expire at 12:00 midnight New York City time, at the end of the day on June 7, 2012.
GSK's offer represents a premium of 81 percent to Human Genome Sciences' closing share price of $7.17 on April 18, 2012, the last trading day before Human Genome Sciences publicly disclosed GSK's private offer. GSK continues to believe its offer represents full and fair value and is in the best interests of both companies' shareholders.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.